Close Menu

NEW YORK (GenomeWeb) – Asuragen announced today it has expanded its CE mark on two BCR-ABL tests to enable their use on a Roche platform.

The multiplexed qPCR tests are part of the firms QuantideX portfolio and support therapy cessation for long-term responders to tyrosine kinase inhibitor therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
15
Sponsored by
Combinati

Detection and quantification of SARS-CoV-2 levels in wastewater can be a useful predictor of potential COVID-19 outbreaks. However, the interpretation of the surveillance data can be challenging.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.